capital · May 13, 2026
Bolt Biotherapeutics Reports $7.2 Million Q1 Net Loss and Seeks Additional Funding
Share the canonical public link.
Bolt Biotherapeutics recorded a $7.2 million net loss for Q1 2026, ending March 31 with $23.9 million in cash reserves. Collaboration revenue dropped to $26,000 from $1.2 million in Q1 2025 due to reduced activities with partners like Astellas Pharma. The Redwood City-based firm anticipates operations funding into early 2027 but expresses substantial doubt on going concern without new equity or partnerships. Bolt's accumulated deficit reached $468 million, reflecting R&D expenses on its AGS Technology platform for cancer therapies.
The body justifies a moderate significance score as it details a quarterly net loss and cash position with going concern doubts, which is noteworthy for a biotech firm but not a major event like a large funding round or acquisition; the assigned 0.55 'notable' tier fits without inflation. Information density is high with multiple verifiable facts including dollar amounts ($7.2M loss, $23.9M cash, $468M deficit), dates (Q1 2026, March 31, early 2027), named entities (Bolt Biotherapeutics, Astellas Pharma), and platform (AGS Technology). No analysis is provided, so it adds no strategic insight beyond the headline and body facts.